Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca, Harvard Stem Cell Institute enter five-year diabetes research collaboration
As part of the deal, AstraZeneca will provide funding for a team of investigators at Harvard and will establish an in-house team in Sweden which will work on
As part of the deal, AstraZeneca will provide funding for a team of investigators at Harvard and will establish an in-house team in Sweden which will work on
AG-348 is a first-in-class, orally available activator of pyruvate kinase-R (PKR) enzymes and the medicine met its primary endpoints in two Phase I healthy volunteer trials including a
NuThrax is a combination of BioThrax (Anthrax Vaccine Adsorbed) and the immunostimulatory oligodeoxynucleotide compound CPG 7909. The contract includes a 30-month base period of performance to develop NuThrax
In the trial, NGM282 showed statistically significant, dose-dependent and clinically meaningful reductions in alkaline phosphatase (ALP), a primary indicator of disease activity, as well as substantial reductions in
The probiotic strains used in HLC Baby B and HLC Baby F probiotic formulas were evaluated in a recent clinical trial, in which they were found to be
The new laboratory space, located within the Human BioMolecular Research Institute, provides Regen with access to molecular and cellular biology facilities critical to its cancer stem cell research.
Canada-based Portage Biotech holds 54% equity of Biohaven, a privately-held biopharmaceutical firm engaged in the identification and development of clinical stage neuroscience compounds targeting the glutamatergic system. Catalent’s
A total of 834 patients were included in the trial and were given Keytruda 10mg/kg every three weeks, Keytruda 10mg/kg every two weeks, or four cycles of ipilimumab
According to the company, the combination was generally well tolerated and all patients completed 12 weeks of treatment. The trial evaluated two doses of VX-661 100mg once daily
As part of the deal, Can-Fite will receive an upfront payment of C$1.65m and is eligible for milestone payments of up to C$2m and royalties from product sales